Navigation Links
Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
Date:5/13/2013

NEW YORK, May 13, 2013 /PRNewswire/ -- Cadwalader, Wickersham & Taft LLP, a leading counselor to global financial institutions and corporations, announced today that client Elan Corporation, plc, a biotechnology company headquartered in Ireland, will purchase from Theravance, Inc. a 21% participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc:  RELVAR™ ELLIPTA™/BREO™ ELLIPTA™, AORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081) and vilanterol (VI) monotherapy.  In exchange for the participation interest, Elan will make a one-time cash payment to Theravance of $1.0 billion.

The Cadwalader team is led by Christopher Cox (Corporate), Ira Schacter (Corporate) and special counsel Aly El Hamamsy (Corporate) in New York; and Angus Duncan (Capital Markets) and Adam Blakemore (Tax) in London.

In April, Cadwalader also advised Elan in the restructuring of its Tysabri® collaboration with Biogen Idec.  On closing of the transaction, Elan received a cash payment of $3.25 billion, together with a double-digit, tiered royalty right on future worldwide net sales of Tysabri®. 

About Cadwalader, Wickersham & Taft LLP

Cadwalader, Wickersham & Taft LLP, established in 1792, serves a diverse client base, including many of the world's leading financial institutions and corporations in more than 50 countries. With offices in New York, London, Charlotte, Washington, Houston, Beijing, Hong Kong and Brussels, Cadwalader offers legal expertise in antitrust, banking, business fraud, corporate finance, corporate governance, energy, environmental, financial restructuring, health care, intellectual property, litigation, mergers and acquisitions, private equity, private wealth, real estate, regulation, securitization, structured finance and tax. For more information, visit www.cadwalader.com.

Contacts:

Adam Segall +1 212 504 6492
adam.segall@cwt.com
Robert Robertson +1 212 504 6897
robert.robertson@cwt.com

 


'/>"/>
SOURCE Cadwalader, Wickersham & Taft LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Couple Catches Bed Bug in a Hotel, My Cleaning Products Advises Hotel Management to Counter the Pests With Non-Pesticide Bed Bug Spray Bed Bug Bully
2. Woman Menaces Worker Trying to Get Rid of Bed Bugs, My Cleaning Products Advises She Gets a Non-Pesticide Bed Bug Spray if She Wants No Help
3. Bed Bugs Rise in Oneida County, My Cleaning Products Cautions Residents and Advises Them to Have a Bed Bug Bully Prepared
4. Bed Bugs Sneak In to Elementary Schools, My Cleaning Products Advises to Officials and Other Bed Bug Victims Use of Pesticide-Exempt Bed Bug Bully
5. Exterminate Bed Bugs Like a Professional, My Cleaning Products Publishes a New Guide and Advises Use of Bed Bug Bully to Help
6. MTA Releases Image of R Train Ceiling Rusting from Sandy Flooding; Rusty Cage Advises Hurricane Victims to Solve Rust Problems with Green Rusterizer
7. Bed Bugs Find Their Way to University of Washington and Hastings-on-Hudson Libraries; Bed Bug Control 911 Advises Use of Bed Bug Spray to Effectively Clear the Pests Away
8. Relief Organizations Worry Sandy Clothing Donations Would Start Bed Bug Epidemic; Bed Bug Removal Guide Advises Disaster Victims to Prepare for It with Bed Bug Bully
9. Rust Gets Toyota Recalling Its Tacoma; Hub on Wheels Advises Car Owners to Deal With Any Other Car Rust Problem with Rusterizer
10. Bed Bugs Bite on Businesses, Green Bean Buddy Advises Owners to Fight Back With a Non-Toxic Bed Bug Bully Product
11. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers ... from small lab samples to full-size tissues, bones, even whole organs to implant ... system that delivers blood deep into the developing tissue. , Current bioengineering ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, ... their live events series, “Stem Cell Therapy: The Next Phase in the Evolution of ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):